The debate over the cost of prescription drugs rages on, even within the pharmaceutical industry.

A recent op-ed in Forbes by John LaMattina, a pharmaceutical analyst, about GlaxoKlineSmith CEO Andrew Witty demonstrates the differences of opinion about trends in drug prices.

Witty, who will be leaving his post early next year, has gained attention for saying publicly that the upward trend in the cost of major medicine was "unsustainable."

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.